Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
Authors:
Open Access
- 21 July 2023
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 137 (2) , 200-208
Abstract
Background: Atopic dermatitis (AD) affects approximately 10% of adults worldwide. CM310 is a humanized monoclonal antibody targeting interleukin-4 receptor alpha that blocks interleukin-4 and interleukin-13 signaling. This trial aimed to evaluate the efficacy and safety of CM310 in Chinese adults with moderate-to-severe AD. Methods: This multicenter, randomized, double-blind, placebo-controlled, phase 2b trial was conducted in 21 medical institutions in China from February to November 2021. Totally 120 eligible patients were enrolled and randomized (1:1:1) to receive subcutaneous injections of 300 mg CM310, 150 mg CM310, or placebo every 2 weeks for 16 weeks, followed by an 8-week follow-up period. The primary endpoint was the proportion of patients achieving ≥75% improvement in the Eczema Area and Severity Index (EASI-75) score from baseline at week 16. Safety and pharmacodynamics were also studied. Results: At week 16, the proportion of EASI-75 responders from baseline was significantly higher in the CM310 groups (70% [28/40] for high-dose and 65% [26/40] for low-dose) than that in the placebo group (20%[8/40]). The differences in EASI-75 response rate were 50% (high vs. placebo, 95% CI 31%–69%) and 45% (low vs. placebo, 95% CI 26%–64%), with both P values <0.0001. CM310 at both doses also significantly improved the EASI score, Investigator's Global Assessment score, daily peak pruritus Numerical Rating Scale, AD-affected body surface area, and Dermatology Life Quality Index compared with placebo. CM310 treatment reduced levels of thymus and activation-regulated chemokine, total immunoglobulin E, lactate dehydrogenase, and blood eosinophils. The incidence of treatment-emergent adverse events (TEAEs) was similar among all three groups, with the most common TEAEs reported being upper respiratory tract infection, atopic dermatitis, hyperlipidemia, and hyperuricemia. No severe adverse events were deemed to be attributed to CM310. Conclusion: CM310 at 150 mg and 300 mg every 2 weeks demonstrated significant efficacy and was well-tolerated in adults with moderate-to-severe AD.Keywords
This publication has 22 references indexed in Scilit:
- Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysisJournal of the American Academy of Dermatology, 2018
- Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic ItchCell, 2017
- Type 2 immunity in tissue repair and fibrosisNature Reviews Immunology, 2017
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trialThe Lancet, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2017
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic DermatitisNew England Journal of Medicine, 2016
- Clinical Features of Adult/Adolescent Atopic Dermatitis and Chinese Criteria for Atopic DermatitisChinese Medical Journal, 2016
- Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialThe Lancet, 2016
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic DermatitisNew England Journal of Medicine, 2014
- Management of Itch in Atopic DermatitisSeminars in Cutaneous Medicine and Surgery, 2011